Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech

Eterna Therapeutics ( (ERNA) ) has issued an update.

Eterna Therapeutics Inc. has entered into an exclusive licensing and collaboration agreement with Factor Bioscience Limited, obtaining rights to develop technology for cancer, autoimmune disorders, and rare diseases. The agreement, which replaces previous arrangements, includes provisions for development support, material supply, and the option for co-development partnerships. Eterna will make monthly payments, cover patent costs, and provide milestone and royalty payments, with an initial term of one year that automatically renews.

Find detailed analytics on ERNA stock on TipRanks’ Stock Analysis page.